Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026)
Novartis Ag (NVS) posted Income from Non-Controlling Interests of -$7.0 million for Q2 2026, down 40.0% sequentially from -$5.0 million in Q4 2025, and up 58.82% YoY from -$4.4 million in Q2 2025.
Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Novartis Ag has reported Income from Non-Controlling Interests for 18 years, with the latest figure at -$7.0 million in Q2 2026.
- Quarterly Income from Non-Controlling Interests rose 58.82% year-over-year to -$7.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$10.0 million (up 37.5% YoY) and the FY2025 annual result came in at -$17.0 million, down 750.0% from the prior year.
- Income from Non-Controlling Interests slipped to -$7.0 million in Q2 2026 per NVS's latest filing, from -$5.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $3.0 million in Q1 2025 and troughed at -$17.0 million in Q2 2025.
- A 5-year average of -$1.5 million and a median of $1.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests jumped 200.0% in 2022, then slumped 350.0% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$2.0 million in 2022, then surged by 200.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then plunged by 350.0% to -$5.0 million in 2025, then sank by 40.0% to -$7.0 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$7.0 million, -$5.0 million, and $2.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 10.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 741.95 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 39.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.00 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -17.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | -2.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | -3.00 Mn |
| Dec 31, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | -3.00 Mn |
| Mar 31, 2020 | -3.00 Mn |